Hello!
I would need to orientate myself in one aspect of the industrial production of therapeutic monoclonal antibodies.
I understand the technologies used for their development (hybrioma, phage display, transgenic mouse, single B cell...). But are these technologies used for the massive production of therapeutic antibodies, or are they only used for their development, and a suitable gene is then transferred to a cell line (for example, CHO) that is massively cultured in bioreactors? If someone asked you how rituximab is prepared in the company (not in the development laboratory), what would you say? Thanks!
Dear Dr. Ondrej Soucek
I am not aware of specific molecule like rituximab. But in general, large-scale production of monoclonal antibodies utilizes mammalian production systems followed by cell removal and purification through sequential chromatographic and membrane filtration steps, to consistently reduce product- (for instance, protein variants) and non-product-related (for instance, host cell proteins) impurities to acceptable levels.
You may want to refer to the article attached below for more information.
https://www.sciencedirect.com/science/article/abs/pii/S0167779910000314#:~:text=Large%2Dscale%20production%20of%20mAbs,proteins)%20impurities%20to%20acceptable%20levels.
Regards
Malcolm Nobre
Hey, feel free to contact us. We are happy to help. Best, Fabian
https://www.capricorn-scientific.com/CHOventure?utm_source=newsletter&utm_medium=organic&utm_campaign=cho_mailshot_27-05-24
- Badges
- Science topic
- Similar topics
- Chemistry
- Pharmacology
- Pharmaceuticals
- Drugs